-
2022-503013-32-00
4
2024-01-29
ER-positive/HER2-negative early breast cancer
-
2023-504487-41-00
5
2023-11-28
COVID-19
-
2022-501895-25-00
5
2023-09-13
Polymyalgia Rheumatica
-
2022-501020-19-01
5
2023-07-31
COVID-19
-
2022-500121-33-01
5
2023-05-08
Anti-GBM antibody disease (Goodpasture disease)
-
2024-513992-42-00
10
2022-09-13
venous thromboembolism (VTE) in patients with gastrointestinal/genitou
-
2022-500363-12-00
4
2022-08-24
SARS CoV-2 (COVID-19)
-
2023-509569-19-00
10
2022-08-10
venous thromboembolism (VTE)
-
2022-501132-42-00
6
2022-08-02
Monkeypox virus disease
-
2023-505457-40-00
5
2022-02-02
Previously Untreated Advanced Gastric or Gastroesophageal Junction
Can
-
2024-516945-37-00
2
2021-11-04
Relapsed/ refractory multiple myeloma
-
2024-511066-36-00
5
2021-10-13
Light Chain (AL) Amyloidosis
-
2022-500385-99-00
5
2021-06-03
SARS-CoV II infection (Coronavirus disease)
-
2023-510230-84-00
5
2021-05-28
Severe asthma with an eosinophilic phenotype
-
2023-506919-18-00
5
2021-05-17
Mild cognitive impairment (MCI) or mild dementia, both of the Alzheime
-
2023-504991-31-00
5
2021-05-06
Agitation in Patients With Dementia of the Alzheimer's Type
-
2023-507024-24-00
5
2020-05-05
Metastatic hormone sensitive prostate cancer
-
2022-501972-25-00
5
2020-04-06
Locally Advanced Cervical Cancer
-
2022-500418-24-00
10
2020-01-17
Locally Recurrent Inoperable or Metastatic Triple Negative Breast Canc
-
2024-511972-33-00
5
2019-08-05
Primary myelofibrosis, post-polycythemia vera myelofibrosis , or post-
-
2022-501970-20-01
5
2019-06-07
Cis-eligible Muscle-invasive bladder cancer.
-
2023-508832-68-00
9
2019-03-28
Recurrent or stage IVB cervical cancer
-
2022-500797-34-00
4
2018-12-17
Treatment of participants with positive cancer for HRRm or HRD.
-
2022-501382-49-00
5
2017-03-07
Triple Negative Breast Cancer (TNBC)